>PARTNERSHIP >Partnership Opportunities Sought
We aspire to discover, develop and commercialize truly innovative treatments that satisfy unmet medical needs regionally and globally. We have focused our resources on therapeutic areas with a substantial potential for growth and, with our partners, we will deliver ground-breaking new treatments to patients worldwide.
Takeda is seeking pre-registration, registration and in-market late stage opportunities in our core therapeutic areas: cardiovascular/metabolic, immunology and respiratory, oncology, central nervous system, GI, renal, general medicine and vaccines. For commercial stage assets, we consider single-country as well as regional deals or agreements covering the globe. Our goal is to identify opportunities that allow us to leverage our global infrastructure to bring products to market that address unmet patient needs. We are interested in opportunities for both ethical and over-the counter medications. In the United States, our interest is in ethical compounds only.
We are seeking multiple and diverse external opportunities including:
Takeda has a strong heritage in the cardiovascular and metabolic areas. Our expertise in this area is demonstrated in the early introduction of the alpha glucosidase inhibitor voglibose (BASEN) and the PPAR-µ pioglitazone (ACTOS), followed more recently by the DPP4 inhibitor alogliptin (NESINA). Our current development interests extend into treatments for obesity and metabolic syndrome, as well as innovative treatments that provide A1c lowering benefits for people with type 2 diabetes.
Our commitment to cardiovascular disease is marked by the early introduction of candesartan to the global market, followed more recently by the launch of azilsartan medoxomil (EDARBI), which recently received Marketing Authorization in Europe and is currently available in the United States and Mexico; and available as azilsartan (AZILVA) in Japan. Our focus on the treatment of hypertension continued with the recent approval and launch of azilsartan medoxomil/chlorthalidone (EDARBYCLOR) in the United States. Our development interests extend into cardiovascular disease areas with high unmet need, such as heart failure, critical limb ischemia and atrial fibrillation.
The Takeda oncology business represents a critical long-term growth driver for the organization. Takeda has made significant investment in the therapeutic area, both internally and through external strategic business transactions including acquisitions, licensing and collaborations, with the goal of achieving a leadership position over the long-term. Millennium, the Takeda Oncology Company, leads oncology research, development and commercialization strategy within Takeda.
The Takeda oncology business is built on blockbuster products which emerged from the application of results from Nobel Prize-winning research. VELCADE is the global market-leading therapy in terms of patient share for multiple myeloma, and LUPRON, the global foundational therapy for prostate cancer.
Takeda boasts a world-class development pipeline of over 20 compounds in hematologic and solid tumors. Late-stage assets are in development for multiple myeloma, prostate cancer and lymphomas.
The oncology Research and Development organization is focused on advancing first-in-class molecules and best-in-class drug combinations. The focus areas of biological expertise include hormonal agents and molecular receptors; protein quality control including ubiquitin-like pathway regulation of protein homeostasis; and signal transduction.
The heterogenous nature of cancer biology places unique demands on companies aspiring to oncology leadership. As such, translational research is integrated throughout research and development to optimize clinical trials and the benefit/risk ratio of our drugs through the use of pharmacodynamic biomarkers in decision making and the implementation of patient selection strategies when feasible in the face of cancer heterogeneity and adaptive resistance.
We engage the full spectrum of academic, venture capital and industry partners to supplement our extensive internal activities in oncology.
We have a strong track record in immunology in the Japanese market and are committed to globalizing that expertise and expanding our portfolio of products. Currently, we market etanercept (ENBREL) under license for the treatment of rheumatoid arthritis in Japan and febuxostat (ULORIC) and colchicine (COLCRYS) for the treatment of gout in the United States. We are conducting late-stage clinical studies for tofacitinib and plan to launch this small molecule kinase inhibitor in Japan in the near future. We are focused on expanding into novel small or large molecule immunology agents to support both our early and late-stage development efforts.
We seek disease modifying drugs with acceptable safety profiles to be administered either as monotherapy or in combination with existing disease modifying drugs. For large molecules we seek agents targeting novel targets, innovative agents and technologies, and agents with superior efficacy and/or safety relative to current treatments. For small molecules we seek both first-in-class (novel MOA) and best-in-class (clear differentiation) candidates. Some preferred MOAs are modulation of Th17/Treg/DC activation/differentiation, multi-cytokine blocking therapies, regulation of innate immune biology, agents targeting activated immune-cell specific metabolism, monocyte activation and trafficking, and tolerance induction.
Takeda Immunology seeks to partner with companies eager to advance the promise of better drugs for the treatment of autoimmune diseases.
In the area of respiratory medicine, we are exploring novel oral and inhaled drugs, biologics and innovative inhaled delivery platforms. Our current development interests extend beyond asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD) to include infant and adult respiratory distress syndrome, cystic fibrosis, and idiopathic pulmonary fibrosis. Takeda is currently only looking for late preclinical stage or clinical stage opportunities in this area.
Takeda recently reaffirmed its commitment to CNS disorders: we aim to discover, develop and deliver innovative and truly differentiated medications for people suffering from psychiatric and neurodegenerative disorders. Our marketed CNS products include the melatonin (MT1/MT2) receptor agonist ramelteon (ROZEREM), available in the United States and Japan, and galantamine (REMINYL), co-marketed in Japan with Janssen. We proactively invest in internal and external compounds and in technologies, as well as in mutually beneficial research collaborations. Our commitment to productive clinical development partnerships is illustrated by our active collaborations in mood disorders (Lu AA21004, with Lundbeck), schizophrenia (lurasidone [LATUDA], with Dainippon Sumitomo), and Alzheimer's disease prevention (AD4833/TOMM40 insulin sensitizer/biomarker assay, with Zinfandel Pharmaceuticals).
General Medicine is built on our foundational products and seeks to exploit our demonstrated scientific and commercial leadership in gastroenterology. In gastroenterology, we have achieved significant success with lansoprazole (Prevacid ), dexlansoprazole (DEXILANT) pantoprazole (PANTOZOL) and lubiprostone (AMITIZA). Innovative medicines are being developed for upper GI disorders, inflammatory bowel disease, and treatment of anemia in chronic kidney disease. Our core focus in General Medicine is on select gastrointestinal and renal diseases, as well as other treatments that have the potential to address unmet need.
We aspire to become a global leader in vaccines. To achieve this goal, we will build on our heritage as a major supplier of pediatric vaccines in Japan for the past 60 years. We are particularly interested in identifying and working with partners to develop prophylactic vaccines for unmet disease states. Vaccines currently under development by Takeda for the Japanese market include pediatric combination vaccines and a haemo-philus influenza type b vaccine, which is currently in Phase 3 trials.
Takeda CMCC is the corporate division responsible for supplying clinical trial materials (CTM) to support Takeda development projects. The three important areas of focus are: 1) Timely supply of CTM; 2) Improvement of drug product through application of new technologies to increase patient value; 3) Optimization of the manufacturing processes for drug substance and drug product to improve efficiency, environmental impact and cost.
Innovative Technologies for Pharmaceutical Science
External innovation is vital to the successful achievement of our objectives and Takeda CMCC is seeking collaborations on a wide variety of novel pharmaceutical science technologies that can add or create new pipeline value. CMCC works on four drug modalities: small molecules, biologics (monoclonal antibody and protein), synthetic polymer drugs (oligonucleotide, peptide and oligosaccharide) and vaccines.
We also have capabilities to identify drug repositioning and new combination opportunities to provide novel therapeutic options for unmet medical needs. External expertise and technologies that can generate extra value are of interest.
In addition to opportunities specific to a therapeutic area, we also seek cross-therapeutic area alliance opportunities on platform technologies for drug discovery. To increase the productivity of our drug discovery, we opened a new research center near Tokyo in Shonan, Japan, in February 2011; this center serves as the hub of Takeda's global network of drug discovery. We seek partnership opportunities, including licensing of proprietary platform technologies and research collaborations based on novel platforms.
We look for alliance partners in all technical areas of drug discovery including:
New Frontier Science (NFS) was established to support scientists who are conceiving ground-breaking life science technologies and to nurture translation of their ideas from concept to reality. Our goal is to work closely with innovators and to provide guidance, resources and financing to advance their vision from conception through key proof of concept experiments.
Takeda will act as the point of entry for innovation by brokering connections between NFS-supported groups and researchers, investors and development partners within Takeda. We are focused on academic medical centers, research institutions, incubators and nascent companies around the world.
In addition to Takeda's traditional business focus on novel pharmaceutical agents, we are interested in adjacent technologies such as diagnostics, devices or business practices that would influence pharmaceutical development, as well as patients and their use of pharmaceutical products.
Our mission is to partner with life science innovators in their quest to conceive of, and realize, therapies that provide true and substantial clinical benefits to patients.
Takeda Ventures, Inc. (TVI) is our corporate venture arm. Our mission is to support the development of external therapeutic innovation that is strategically aligned with Takeda's R&D imperatives and that offers the potential to realize new, advanced healthcare options for patients worldwide. We do this by investing in pharmaceutical technology and product concepts and by fostering highly effective management teams that can turn ideas into reality.
As a strategic investor, we aim to encourage and support therapeutic innovation in the biopharmaceutical sector, as well as academic centers of excellence, through early stage capital investment and access to the resources of a multinational pharmaceutical company. The geographic scope of investments includes North America, Europe and the Pacific Rim territories, including Japan. While we will consider product, target and technology opportunities at any stage, our focus is on start-up/seed rounds through mid-stage financing. We will consider follow-on rounds of investment where the strategic intent remains true and further funding is required to drive projects to fruition.
We maintain a diverse investment portfolio with a concentration on drugs and biotherapeutics to treat cancer, metabolic disorders (obesity, diabetes and dyslipidemias), cardiovascular disorders, chronic inflammatory and immune disorders (gastrointestinal and bone and joint disorders) and diseases of the central nervous system (Alzheimer's disease and schizophrenia). Additional areas of strategic importance include regenerative medicines, RNA and DNA modulation, protein and peptide drug delivery systems, novel vaccine technologies and innovative protein and peptide biotherapeutics.